top of page
VERESCA PRECISION ONCOLOGY 3NDx OTI.png

Investigator - Initiated Trial Evaluation Program

Enlist the support of Veresca Precision Oncology to improve the clinical efficacy of your MultiRx evaluation through patient enrichment using the Veresca FOXC1 Test.

Screenshot (962).png

Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression. 

​

Presented by:  Partha S. Ray, MD

Oral Mini Session 2 - LBA 1

15:10  | 08 Dec 2022 | Room B

​

Screenshot (963)_edited.jpg

Embargoed Until 10 DEC 22

Screenshot (772).png

ESMO Oral Presentation LBA2

Frankfurt Hall

5 May 2022 10:45 am (CEST)

Onconostic Technologies, Inc.

 Partha S. Ray, MD

​

​

Assessment  of Ki67 and FOXC1-based response predictor tracking proliferation and plasticity as a complementary diagnostic for neoadjuvant Olaparib + Paclitaxel + Darvlumab in primary TNBC: retrospective analysis of the I-SPY Trial

VID220519 VIDEO COVER.png
Screenshot (957).png

EMUC Presentation

Poster EPO 29

Screenshot (960)_edited.jpg
Screenshot (777).png

ASCO Presentation 

Abstract 569 - Poster 341 

title.png
labortorio e oncologia.png
gregorio maranon.png
VERESCA PRECISION ONCOLOGY 3NDx OTI.png
ESMO 2022 PRSENTATION
bottom of page